F. Adrian Casavilla, MD; Robert Gordon, MD; Harlan I. Wright, MD; Judith S. Gavaler, PhD; Thomas E. Starzl, MD; David H. Van Thiel, MD
The effects of liver transplantation and the obligate use of cyclosporine on the subsequent clinical course of nine patients with sarcoidosis were examined. Two comparison groups, each consisting of 18 patients without sarcoidosis, were also studied. The liver allograft recipients received either cyclosporine or FK 506 as their primary immunosuppressive agent. Patient and graft survival were assessed for all three groups. In patients with sarcoidosis before transplantation, evidence for continued disease activity after transplantation was also assessed. Patient and allograft survival were excellent. No clinical evidence of continued disease activity was noted. Thus, the presence of sarcoidosis is not a contraindication for liver transplantation in otherwise appropriate candidates for the procedure.
Casavilla FA, Gordon R, Wright HI, Gavaler JS, Starzl TE, Van Thiel DH. Clinical Course after Liver Transplantation in Patients with Sarcoidosis. Ann Intern Med. ;118:865–866. doi: 10.7326/0003-4819-118-11-199306010-00007
Download citation file:
Published: Ann Intern Med. 1993;118(11):865-866.
Gastroenterology/Hepatology, Liver Disease, Liver Transplantation.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use